← Back to Search

Insulin

MiniMed 780G System for Type 1 Diabetes

N/A
Waitlist Available
Research Sponsored by Medtronic Diabetes
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months
Awards & highlights

Study Summary

This trial will study the safety of using Lyumjev insulin lispro to treat type 1 diabetes in children and adults at home.

Eligible Conditions
  • Type 1 Diabetes

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Primary Effectiveness Endpoint for Age 18-80 - Percent of Time in Range (TIR 70-180 mg/dL)
Primary Effectiveness Endpoint for Age 7-17 - Percent of Time in Range (TIR 70-180 mg/dL)
Primary Safety Endpoint for Age 18-80 - Change in HbA1c
+1 more
Secondary outcome measures
Secondary Effectiveness Endpoint 1 for Age 18-80 - Percent of Time in Hypoglycemia (< 54 mg/dL)
Hypoglycemia
Secondary Effectiveness Endpoint 2 for Age 18-80 - Percent of Time in Range (TIR 70-180 mg/dL)
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: MiniMed 780G System Utilizing Insulin Lyumjev®Experimental Treatment1 Intervention
Subjects with insulin-requiring type 1 diabetes age 7-80 using the MiniMed 780G system with Insulin Lyumjev® for a period of three months.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MiniMed 780G System
2022
N/A
~250

Find a Location

Who is running the clinical trial?

Medtronic DiabetesLead Sponsor
67 Previous Clinical Trials
9,757 Total Patients Enrolled
Eli Lilly and CompanyIndustry Sponsor
2,624 Previous Clinical Trials
3,216,680 Total Patients Enrolled

Media Library

Lyumjev® lispro-aabc (Insulin) Clinical Trial Eligibility Overview. Trial Name: NCT05325294 — N/A
Type 1 Diabetes Research Study Groups: MiniMed 780G System Utilizing Insulin Lyumjev®
Type 1 Diabetes Clinical Trial 2023: Lyumjev® lispro-aabc Highlights & Side Effects. Trial Name: NCT05325294 — N/A
Lyumjev® lispro-aabc (Insulin) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05325294 — N/A
~81 spots leftby May 2025